Filter

News

EFFECTS OF ALT 801, A GLP 1 AND GLUCAGON RECEPTOR DUAL AGONIST, IN A TRANSLATIONAL MOUSE MODEL OF NON ALCOHOLIC STEATOHEPATITIS

Nestor, J.J., Parkes, D., Feigh, M., Suschak, J.J. and Harris, M.S. Scientific Reports (2022) 12:6666…
News

DESIGN AND CHARACTERIZATION OF A SURFACTANT-CONJUGATED, LONG-ACTING, BALANCED GLP-1/GLUCAGON RECEPTOR DUAL AGONIST.

Nestor J.J., Jr., Zhang, X., Jaw-Tsai, S., Parkes, D.G., and Becker, C.K. Peptide Science. (2021);113:e24221.…
News

SURFACTANT-MODIFIED PARATHYROID HORMONE FRAGMENTS WITH HIGH POTENCY AND PROLONGED ACTION: STRUCTURE-INFORMED DESIGN USING GLYCOLIPID SURFACTANT CONJUGATION

Nestor, J.J., Jr. and Wang, W. Peptide Science (2021); e24225 doi.org/10.1002/pep2.24225 Abstract: The pharmaceutical properties…
News

PEPTIDE DEVELOPMENT GOES VIRTUAL

Genetic Engineering and Biotechnology News Jan. 15, 2013 GEN News Highlights. Velocity Pharmaceutical Development (VPD) will…
News

VELOCITY PHARMACEUTICAL DEVELOPMENT ANNOUNCES CLINICAL DEVELOPMENT AGREEMENT

SOUTH SAN FRANCISCO, Jan. 15, 2013 /PRNewswire/ -- Velocity Pharmaceutical Development LLC (VPD) today announced…
News

PHARMA LICENSING DEAL YIELDS VIRTUAL STARTUP THAT’S OPTIMIZING PEPTIDE DRUGS, RAISING $9.5M

JANUARY 21, 2013 A licensing deal between two California pharmaceutical companies has resulted in the…
News

THE MEDICINAL CHEMISTRY OF PEPTIDES

Nestor, J.J., Jr. (2009) Curr Med Chem 16(33): pp4399-4418. DOI: 10.2174/092986709789712907 Abstract: The shortcomings of native…